coumarin has been researched along with Alzheimer Disease in 21 studies
2H-chromen-2-one: coumarin derivative
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coumarins are a large family of compounds, of natural and synthetic origin, that exhibit a variety of pharmacological activities, including MAO inhibition." | 6.49 | A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease. ( Bari, SB; Deshmukh, PK; Donda, ST; Firke, SD; Patil, DA; Patil, PO, 2013) |
| "Coumarins are a large family of compounds, of natural and synthetic origin, that exhibit a variety of pharmacological activities, including MAO inhibition." | 2.49 | A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease. ( Bari, SB; Deshmukh, PK; Donda, ST; Firke, SD; Patil, DA; Patil, PO, 2013) |
| "Due to the complex nature of Alzheimer's disease, there is a renewed search for pleiotropic agents." | 1.42 | Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease. ( Hadjipavlou-Litina, DJ; Kallitsakis, MG; Litinas, KE; Marco-Contelles, J; Soriano, E; Yañez, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shaik, JB | 1 |
| Kandrakonda, YR | 1 |
| Kallubai, M | 1 |
| Gajula, NN | 1 |
| Dubey, S | 1 |
| Aramati, BMR | 1 |
| Subramanyam, R | 1 |
| Amooru, GD | 1 |
| Hasan, AH | 1 |
| Murugesan, S | 1 |
| Amran, SI | 1 |
| Chander, S | 1 |
| Alanazi, MM | 1 |
| Hadda, TB | 1 |
| Shakya, S | 1 |
| Pratama, MRF | 1 |
| Das, B | 1 |
| Biswas, S | 1 |
| Jamalis, J | 1 |
| Sharma, A | 1 |
| Nuthakki, VK | 1 |
| Gairola, S | 1 |
| Singh, B | 1 |
| Bharate, SB | 1 |
| Jiang, X | 1 |
| Guo, J | 1 |
| Lv, Y | 1 |
| Yao, C | 1 |
| Zhang, C | 2 |
| Mi, Z | 1 |
| Shi, Y | 1 |
| Gu, J | 2 |
| Zhou, T | 2 |
| Bai, R | 2 |
| Xie, Y | 2 |
| Singh, A | 1 |
| Sharma, S | 1 |
| Arora, S | 1 |
| Attri, S | 1 |
| Kaur, P | 1 |
| Kaur Gulati, H | 1 |
| Bhagat, K | 1 |
| Kumar, N | 1 |
| Singh, H | 1 |
| Vir Singh, J | 1 |
| Mohinder Singh Bedi, P | 1 |
| Amin, KM | 1 |
| Abdel Rahman, DE | 1 |
| Abdelrasheed Allam, H | 1 |
| El-Zoheiry, HH | 1 |
| Mzezewa, SC | 1 |
| Omoruyi, SI | 1 |
| Zondagh, LS | 1 |
| Malan, SF | 1 |
| Ekpo, OE | 1 |
| Joubert, J | 1 |
| Yang, HL | 1 |
| Cai, P | 1 |
| Liu, QH | 1 |
| Yang, XL | 1 |
| Li, F | 2 |
| Wang, J | 2 |
| Wu, JJ | 2 |
| Wang, XB | 2 |
| Kong, LY | 4 |
| Jiang, N | 3 |
| Huang, Q | 1 |
| Liu, J | 1 |
| Liang, N | 1 |
| Li, Q | 2 |
| Xie, SS | 4 |
| Hiremathad, A | 1 |
| Chand, K | 1 |
| Keri, RS | 1 |
| Jalili-Baleh, L | 1 |
| Forootanfar, H | 1 |
| Küçükkılınç, TT | 1 |
| Nadri, H | 1 |
| Abdolahi, Z | 1 |
| Ameri, A | 1 |
| Jafari, M | 1 |
| Ayazgok, B | 1 |
| Baeeri, M | 1 |
| Rahimifard, M | 1 |
| Abbas Bukhari, SN | 1 |
| Abdollahi, M | 1 |
| Ganjali, MR | 1 |
| Emami, S | 1 |
| Khoobi, M | 1 |
| Foroumadi, A | 1 |
| Yang, K | 1 |
| Yu, S | 1 |
| Su, J | 1 |
| Yuan, S | 1 |
| Han, J | 1 |
| Chen, Y | 1 |
| Patil, PO | 1 |
| Bari, SB | 1 |
| Firke, SD | 1 |
| Deshmukh, PK | 1 |
| Donda, ST | 1 |
| Patil, DA | 1 |
| Bag, S | 1 |
| Ghosh, S | 1 |
| Tulsan, R | 1 |
| Sood, A | 1 |
| Zhou, W | 1 |
| Schifone, C | 1 |
| Foster, M | 1 |
| LeVine, H | 1 |
| Török, B | 1 |
| Török, M | 1 |
| Li, JY | 1 |
| Yang, L | 1 |
| Kallitsakis, MG | 1 |
| Yañez, M | 1 |
| Soriano, E | 1 |
| Marco-Contelles, J | 1 |
| Hadjipavlou-Litina, DJ | 1 |
| Litinas, KE | 1 |
| Wang, X | 2 |
| Yu, W | 1 |
| Wang, KD | 1 |
| Lan, JS | 2 |
| Li, ZR | 1 |
| Wang, ZM | 1 |
| Smith, B | 1 |
| Medda, F | 1 |
| Gokhale, V | 1 |
| Dunckley, T | 1 |
| Hulme, C | 1 |
| Catto, M | 1 |
| Pisani, L | 1 |
| Leonetti, F | 1 |
| Nicolotti, O | 1 |
| Pesce, P | 1 |
| Stefanachi, A | 1 |
| Cellamare, S | 1 |
| Carotti, A | 1 |
| Kontogiorgis, CA | 1 |
| Xu, Y | 1 |
| Hadjipavlou-Litina, D | 1 |
| Luo, Y | 1 |
2 reviews available for coumarin and Alzheimer Disease
| Article | Year |
|---|---|
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
Topics: Alzheimer Disease; Coumarins; Depression; Drug Design; Humans; Models, Molecular; Molecular Structur | 2013 |
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Topics: Alzheimer Disease; Animals; Anthraquinones; Biomedical Research; Carbolines; Catechin; Chromosomes, | 2012 |
19 other studies available for coumarin and Alzheimer Disease
| Article | Year |
|---|---|
Deciphering the AChE-binding mechanism with multifunctional tricyclic coumarin anti-Alzheimer's agents using biophysical and bioinformatics approaches and evaluation of their modulating effect on Amyloidogenic peptide assembly.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Computational Biol | 2021 |
Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation.
Topics: Acetylcholinesterase; Alzheimer Disease; Cells, Cultured; Chalcone; Cholinesterase Inhibitors; Couma | 2022 |
A Coumarin-Donepezil Hybrid as a Blood-Brain Barrier Permeable Dual Cholinesterase Inhibitor: Isolation, Synthetic Modifications, and Biological Evaluation of Natural Coumarins.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Bloo | 2022 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cholinesterase Inh | 2020 |
Design and synthesis of novel coumarin derivatives as potential acetylcholinesterase inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Behavior, Animal; Cholinesterase Inhibitors; Couma | 2021 |
Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer's disease agents.
Topics: Alzheimer Disease; Cell Line, Tumor; Coumarins; Dose-Response Relationship, Drug; Drug Design; Human | 2021 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relations | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell L | 2018 |
Development of coumarin-benzofuran hybrids as versatile multitargeted compounds for the treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Binding Sites; Cholinesterase Inhibitors; Cou | 2018 |
Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer's disease based on coumarin and lipoic acid scaffolds.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cholinesterase Inhibitors; Choline | 2018 |
Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Coumarins; Dose-Response Relationship, | 2019 |
Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Catalytic Domain; Cha | 2013 |
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Couma | 2013 |
Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Coumarins; Glycine max; Humans; Hypolipidemic Agents; Lipoxygenase; Lipoxygenase | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chol | 2016 |
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Chol | 2013 |
Coumarin derivatives protection against ROS production in cellular models of Abeta toxicities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Coumarins; Free Radicals; Human | 2007 |